TJPC(SH:600488) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-05-05 23:09Group 1: Administrative Penalty - The company received an administrative penalty decision from the Tianjin Market Supervision Administration for violating the Anti-Monopoly Law by engaging in price-fixing agreements related to dexamethasone phosphate sodium raw materials [1][2] - The total penalty amounts to 69,192,350.36 yuan, which includes the confiscation of illegal gains of 42,764,400.00 yuan and a fine of 26,427,950.36 yuan after an 80% reduction [2] - The penalty represents 2.15% of the company's audited revenue and 51.85% of the net profit attributable to shareholders for the most recent fiscal year [3] Group 2: Company Impact and Response - The penalty will reduce the company's net profit attributable to shareholders by 69,192,350.36 yuan for 2025, but it does not trigger any mandatory delisting conditions under the Shanghai Stock Exchange rules [3] - The company has implemented corrective measures, including developing a sales plan to lower prices for dexamethasone phosphate sodium, enhancing its anti-monopoly compliance system, and conducting compliance training for all employees [4] Group 3: Product Registration - The company's subsidiary, Tianjin Pharmaceutical Co., Ltd., received a registration certificate from the Dominican Republic's Ministry of Health for its injectable methylprednisolone acetate, allowing it to produce and sell the product in that market [6][8] - The injectable methylprednisolone acetate is a corticosteroid used for anti-inflammatory and immunosuppressive treatments, with global sales of methylprednisolone injection estimated at 526 million USD in 2023 [7]